Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1318

1.

Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Greene SJ, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, Hernandez AF, Matsouaka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2019 Oct 5. pii: S2213-1779(19)30664-X. doi: 10.1016/j.jchf.2019.07.011. [Epub ahead of print]

PMID:
31606362
2.

Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry.

Xian Y, Navar AM, Li S, Li Z, Robinson J, Virani SS, Louie MJ, Koren A, Goldberg A, Roger VL, Wilson PWF, Peterson ED, Wang TY.

J Am Heart Assoc. 2019 Oct;8(19):e013229. doi: 10.1161/JAHA.119.013229. Epub 2019 Sep 26.

3.

Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital?

Rymer JA, Chen AY, Thomas L, Fonarow GC, Peterson ED, Wang TY.

J Am Heart Assoc. 2019 Oct;8(19):e012059. doi: 10.1161/JAHA.119.012059. Epub 2019 Sep 20.

4.

Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.

Spyropoulos AC, Ashton V, Chen YW, Wu B, Peterson ED.

Thromb Res. 2019 Aug 22;182:159-166. doi: 10.1016/j.thromres.2019.08.021. [Epub ahead of print]

5.

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.

Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.

Cardiovasc Diabetol. 2019 Sep 3;18(1):116. doi: 10.1186/s12933-019-0921-2.

6.

Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort.

Butt JH, Li A, Xian Y, Peterson ED, Garcia D, Torp-Pedersen C, Køber L, Fosbøl EL.

Am Heart J. 2019 Jul 25;216:117-124. doi: 10.1016/j.ahj.2019.07.012. [Epub ahead of print]

PMID:
31425898
7.

Sex Differences in the Use of Statins in Community Practice.

Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, Li Z, Peterson ED, Navar AM.

Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005562. doi: 10.1161/CIRCOUTCOMES.118.005562. Epub 2019 Aug 16.

PMID:
31416347
8.

Intravenous Tissue Plasminogen Activator in Stroke Mimics.

Ali-Ahmed F, Federspiel JJ, Liang L, Xu H, Sevilis T, Hernandez AF, Kosinski AS, Prvu Bettger J, Smith EE, Bhatt DL, Schwamm LH, Fonarow GC, Peterson ED, Xian Y.

Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005609. doi: 10.1161/CIRCOUTCOMES.119.005609. Epub 2019 Aug 15.

PMID:
31412730
9.
10.

The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice.

Bradley CK, Shrader P, Sanchez RJ, Peterson ED, Navar AM.

J Clin Lipidol. 2019 Jul 2. pii: S1933-2874(19)30228-4. doi: 10.1016/j.jacl.2019.06.008. [Epub ahead of print]

11.

Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.

Xian Y, Xu H, O'Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Hannah D, Maisch L, Lytle BL, Peterson ED, Hernandez AF.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2099. [Epub ahead of print]

PMID:
31329212
12.

Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy.

Inohara T, Liang L, Kosinski AS, Smith EE, Schwamm LH, Hernandez AF, Bhatt DL, Fonarow GC, Peterson ED, Xian Y.

J Am Heart Assoc. 2019 Aug 6;8(15):e012450. doi: 10.1161/JAHA.119.012450. Epub 2019 Jul 20.

13.

Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.

Jahan R, Saver JL, Schwamm LH, Fonarow GC, Liang L, Matsouaka RA, Xian Y, Holmes DN, Peterson ED, Yavagal D, Smith EE.

JAMA. 2019 Jul 16;322(3):252-263. doi: 10.1001/jama.2019.8286.

PMID:
31310296
14.

Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes.

Nelson AJ, Peterson ED, Pagidipati NJ.

Prog Cardiovasc Dis. 2019 Jul 10. pii: S0033-0620(19)30098-2. doi: 10.1016/j.pcad.2019.07.001. [Epub ahead of print] Review.

PMID:
31301314
15.

Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients.

Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, Wang TY.

Circ Cardiovasc Qual Outcomes. 2019 Jul;12(7):e005103. doi: 10.1161/CIRCOUTCOMES.118.005103. Epub 2019 Jul 9.

PMID:
31284739
16.

Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED, Pencina MJ, Sniderman AD.

J Am Coll Cardiol. 2019 Jul 9;74(1):70-79. doi: 10.1016/j.jacc.2019.04.047.

PMID:
31272554
17.

Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.

Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators.

JAMA Cardiol. 2019 Jul 3. doi: 10.1001/jamacardio.2019.1960. [Epub ahead of print]

18.

Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry.

Nanna MG, Navar AM, Wang TY, Li S, Virani SS, Li Z, Robinson JG, Roger VL, Wilson PWF, Goldberg AC, Koren A, Louie MJ, Peterson ED.

Am Heart J. 2019 Aug;214:113-124. doi: 10.1016/j.ahj.2019.05.009. Epub 2019 May 22.

PMID:
31202098
19.

Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.

Inohara T, Shrader P, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Go AS, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.

Am Heart J. 2019 Jul;213:81-90. doi: 10.1016/j.ahj.2019.04.007. Epub 2019 Apr 24.

PMID:
31129441
20.

Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke.

Dodds JA, Xian Y, Sheng S, Fonarow GC, Bhatt DL, Matsouaka R, Schwamm LH, Peterson ED, Smith EE.

Neurology. 2019 Jun 11;92(24):e2784-e2792. doi: 10.1212/WNL.0000000000007653. Epub 2019 May 15.

PMID:
31092622
21.

Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score.

Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, O'Brien EC, Reiffel JA, Naccarelli GV, Ezekowitz MD, Chan PS, Singer DE, Spertus JA, Peterson ED, Thomas L.

Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358. doi: 10.1161/CIRCOUTCOMES.118.005358.

PMID:
31092022
22.

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.

Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD.

Int J Cardiol. 2019 Aug 15;289:58-62. doi: 10.1016/j.ijcard.2019.04.085. Epub 2019 Apr 30.

PMID:
31079973
23.

Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.

Rymer JA, Kaltenbach LA, Doll JA, Messenger JC, Peterson ED, Wang TY.

J Am Heart Assoc. 2019 May 21;8(10):e012236. doi: 10.1161/JAHA.119.012236.

24.

Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack: A Cluster Randomized Clinical Trial.

Machline-Carrion MJ, Santucci EV, Damiani LP, Bahit MC, Málaga G, Pontes-Neto OM, Martins SCO, Zétola VF, Normilio-Silva K, Rodrigues de Freitas G, Gorgulho A, De Salles A, Pacheco da Silva BG, Santos JY, de Andrade Jesuíno I, Bueno PRT, Cavalcanti AB, Guimarães HP, Xian Y, Bettger JP, Lopes RD, Peterson ED, Berwanger O; BRIDGE-Stroke Investigators.

JAMA Neurol. 2019 May 6. doi: 10.1001/jamaneurol.2019.1012. [Epub ahead of print]

PMID:
31058947
25.

Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.

Ehrlich ME, Liang L, Xu H, Kosinski AS, Hernandez AF, Schwamm LH, Smith EE, Fonarow GC, Bhatt DL, Peterson ED, Xian Y.

Stroke. 2019 Jun;50(6):1497-1503. doi: 10.1161/STROKEAHA.118.024172. Epub 2019 Apr 30.

PMID:
31035901
26.

Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry.

Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW.

J Am Heart Assoc. 2019 May 7;8(9):e011205. doi: 10.1161/JAHA.118.011205.

27.

N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

Peng H, Xu J, Yang XP, Kassem KM, Rhaleb IA, Peterson E, Rhaleb NE.

Can J Physiol Pharmacol. 2019 Aug;97(8):753-765. doi: 10.1139/cjpp-2019-0047. Epub 2019 Apr 18.

PMID:
30998852
28.

Effect of a Quality of Care Improvement Initiative in Patients With Acute Coronary Syndrome in Resource-Constrained Hospitals in China: A Randomized Clinical Trial.

Wu Y, Li S, Patel A, Li X, Du X, Wu T, Zhao Y, Feng L, Billot L, Peterson ED, Woodward M, Kong L, Huo Y, Hu D, Chalkidou K, Gao R; CPACS-3 Investigators.

JAMA Cardiol. 2019 May 1;4(5):418-427. doi: 10.1001/jamacardio.2019.0897.

29.

Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.

Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC.

Am Heart J. 2019 Jun;212:113-119. doi: 10.1016/j.ahj.2019.02.001. Epub 2019 Feb 20.

30.

Acute and 1-Year Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Results From the TRANSLATE-ACS Registry.

Cowper PA, Knight JD, Davidson-Ray L, Peterson ED, Wang TY, Mark DB; TRANSLATE‐ACS Investigators.

J Am Heart Assoc. 2019 Apr 16;8(8):e011322. doi: 10.1161/JAHA.118.011322.

31.

Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States.

Samsky MD, Ambrosy AP, Youngson E, Liang L, Kaul P, Hernandez AF, Peterson ED, McAlister FA.

JAMA Cardiol. 2019 May 1;4(5):444-453. doi: 10.1001/jamacardio.2019.0766. Erratum in: JAMA Cardiol. 2019 Sep 18;:.

PMID:
30969316
32.

Adolescent and Young Adult Recreational, Occupational, and Transportation Activity: Activity Recommendation and Weight Status Relationships.

Moseley CA, Skinner AC, Perrin EM, Armstrong SC, Peterson ED, Wong CA.

J Adolesc Health. 2019 Jul;65(1):147-154. doi: 10.1016/j.jadohealth.2019.01.021. Epub 2019 Apr 1.

PMID:
30948270
33.

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.

Rozjabek HM, Coleman CI, Ashton V, Laliberté F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED.

J Med Econ. 2019 Aug;22(8):751-759. doi: 10.1080/13696998.2019.1603156. Epub 2019 Apr 25.

PMID:
30939954
34.

Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry.

Bradley CK, Wang TY, Li S, Robinson JG, Roger VL, Goldberg AC, Virani SS, Louie MJ, Lee LV, Peterson ED, Navar AM.

J Am Heart Assoc. 2019 Apr 2;8(7):e011765. doi: 10.1161/JAHA.118.011765.

35.

Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.

Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ; ORBIT AF Investigators.

Am Heart J. 2019 May;211:77-89. doi: 10.1016/j.ahj.2019.01.005. Epub 2019 Jan 30.

PMID:
30901602
36.

AHA Scientific Sessions 2018 Highlights.

Peterson ED, Lloyd-Jones D.

Circulation. 2019 Mar 5;139(10):1335-1337. doi: 10.1161/CIRCULATIONAHA.119.039755. No abstract available.

PMID:
30865479
37.

Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry).

Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED.

Am J Cardiol. 2019 May 15;123(10):1628-1636. doi: 10.1016/j.amjcard.2019.02.010. Epub 2019 Feb 23.

PMID:
30846214
38.

Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research.

Navar AM, Peterson ED, Steen DL, Wojdyla DM, Sanchez RJ, Khan I, Song X, Gold ME, Pencina MJ.

JAMA Cardiol. 2019 Apr 1;4(4):375-379. doi: 10.1001/jamacardio.2019.0198.

39.

Specialty certification and clinical flexibility.

Peterson ED, Hussaini SS, Murfin M, Smith BJ, Polansky M, Klingler AM, Peterson PR, Mast J, Wright KA.

JAAPA. 2019 Mar;32(3):43-48. doi: 10.1097/01.JAA.0000553385.82884.f1.

PMID:
30817480
40.

Progression of glucose-lowering diabetes therapy in TECOS.

Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group.

Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan.

41.

Stroke prevention in atrial fibrillation: Closing the gap.

Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM, Kline-Rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB.

Am Heart J. 2019 Apr;210:29-38. doi: 10.1016/j.ahj.2018.10.004. Epub 2018 Oct 25. No abstract available.

PMID:
30731371
42.

Use of left atrial appendage occlusion among older cardiac surgery patients with preoperative atrial fibrillation: a national cohort study.

Friedman DJ, Gaca JG, Wang T, Malaisrie SC, Holmes DR, Piccini JP, Suri RM, Mack MJ, Badhwar V, Jacobs JP, Peterson ED, Chow SC, Matthew Brennan J.

J Interv Card Electrophysiol. 2019 Feb 2. doi: 10.1007/s10840-019-00519-w. [Epub ahead of print]

PMID:
30712076
43.

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.

Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.

Circ Cardiovasc Interv. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124.

PMID:
30704287
44.

Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry).

Lowenstern A, Navar AM, Li S, Virani SS, Goldberg AC, Louie MJ, Lee LV, Peterson ED, Wang TY.

Am J Cardiol. 2019 Apr 1;123(7):1011-1018. doi: 10.1016/j.amjcard.2018.12.031. Epub 2019 Jan 4.

PMID:
30660354
45.

Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort.

Gundlund A, Xian Y, Peterson ED, Butt JH, Gadsbøll K, Bjerring Olesen J, Køber L, Torp-Pedersen C, Gislason GH, Loldrup Fosbøl E.

JAMA Netw Open. 2018 May 18;1(1):e180171. doi: 10.1001/jamanetworkopen.2018.0171.

46.

Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.

Wang TY, Kaltenbach LA, Cannon CP, Fonarow GC, Choudhry NK, Henry TD, Cohen DJ, Bhandary D, Khan ND, Anstrom KJ, Peterson ED.

JAMA. 2019 Jan 1;321(1):44-55. doi: 10.1001/jama.2018.19791.

47.

Quantifying Importance of Major Risk Factors for Coronary Heart Disease.

Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB Sr, Peterson ED, Sniderman AD.

Circulation. 2019 Mar 26;139(13):1603-1611. doi: 10.1161/CIRCULATIONAHA.117.031855.

48.

Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention.

Fanaroff AC, Zakroysky P, Wojdyla D, Kaltenbach LA, Sherwood MW, Roe MT, Wang TY, Peterson ED, Gurm HS, Cohen MG, Messenger JC, Rao SV.

Circulation. 2019 Jan 22;139(4):458-472. doi: 10.1161/CIRCULATIONAHA.117.033325.

PMID:
30586696
49.

Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure.

Greenberg B, Peterson ED, Berger JS, Laliberté F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC.

Clin Cardiol. 2019 Feb;42(2):277-284. doi: 10.1002/clc.23140. Epub 2019 Jan 7.

50.

Gait Speed and 1-Year Mortality Following Cardiac Surgery: A Landmark Analysis From the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

Afilalo J, Sharma A, Zhang S, Brennan JM, Edwards FH, Mack MJ, McClurken JB, Cleveland JC Jr, Smith PK, Shahian DM, Peterson ED, Alexander KP.

J Am Heart Assoc. 2018 Dec 4;7(23):e010139. doi: 10.1161/JAHA.118.010139.

Supplemental Content

Loading ...
Support Center